The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia-Reference-Cited by-同舟云学术

The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia

Published:2018-07 Issue: Volume:70 Page:91-96
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Vulaj Vera,Perissinotti Anthony J.,Uebel James R.,Nachar Victoria R.^ORCID,Scappaticci Gianni B.,Crouch Ashley,Bixby Dale L.,Burke Patrick W.^ORCID,Maillard Ivan,Talpaz Moshe,Marini Bernard L.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference25 articles.

1. The incidence of secondary leukemias;Leone;Haematologica,1999

2. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry;Hulegårdh;Am. J. Hematol.,2015

3. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study;Granfeldt Østgård;J. Clin. Oncol.,2015

4. De novo and secondary acute myeloid leukemia, real world data on outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory;Renaud;Blood,2016

5. Final results of a phase III randomized trial of CPX-351 versus 7 + 3 in older patients with newly diagnosed high risk (secondary);Lancet;AML J. Clin. Oncol.,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment;Laboratory Medicine;2024-07-13

2. Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology;International Journal of Clinical Oncology;2024-05-17

3. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches;Annals of Hematology;2023-09-28

4. Therapy-related core binding factor acute myeloid leukemia;International Journal of Hematologic Oncology;2023-03

5. Oncology stewardship in acute myeloid leukemia;Annals of Hematology;2022-05-26